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esponsibility of InstAbstract Intestine is responsible for the biotransformation of many orally-exposed chemicals. The
constitutive androstane receptor (CAR/Nr1i3) is known to up-regulate many genes encoding drug-
metabolizing enzymes and transporters (drug-processing genes/DPGs) in liver, but less is known
regarding its effect in intestine. Sixty-day-old wild-type and Car / mice were administered the CAR-
ligand TCPOBOP or vehicle once daily for 4 days. In wild-type mice, Car mRNA was down-regulated by
TCPOBOP in liver and duodenum. Car / mice had altered basal intestinal expression of many DPGs in
a section-speciﬁc manner. Consistent with the liver data (Aleksunes and Klaassen, 2012), TCPOBOP up-
regulated many DPGs (Cyp2b10, Cyp3a11, Aldh1a1, Aldh1a7, Gsta1, Gsta4, Gstm1-m4, Gstt1, Ugt1a1,
Ugt2b34, Ugt2b36, and Mrp2–4) in speciﬁc sections of small intestine in a CAR-dependent manner.
However, the mRNAs of Nqo1 and Papss2 were previously known to be up-regulated by TCPOBOP in
liver but were not altered in intestine. Interestingly, many known CAR-target genes were highest
expressed in colon where CAR is minimally expressed, suggesting that additional regulators are involved4
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Shinhee Park et al.476in regulating their expression. In conclusion, CAR regulates the basal expression of many DPGs in
intestine, and although many hepatic CAR-targeted DPGs were bona ﬁde CAR-targets in intestine,
pharmacological activation of CAR in liver and intestine are not identical.
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Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Oral administration is the preferred route by patients due to its
convenience, price, comfort, and handling1. The orally-
administered drugs may undergo extensive ﬁrst-pass metabolism
in the gastro-intestinal tract, and this may result in limited
systematic bioavailability, and decreased therapeutic effects2,3.
Absorption of orally administered drugs takes place primarily in
the small intestine, followed by delivery to the liver via the portal
blood. The small intestine is efﬁcient in the absorption of a wide-
spectrum of chemicals due to the high concentration of villi and
microvilli in the order of duodenum, jejunum, and ileum4,
abundant epithelial transporters, optimal pH for absorption, high
peristalsis, high blood ﬂow, as well as contact for a long time.
Alteration or failure to maintain one of these conditions may result
in lower bioavailability of the drug3,5,6. In addition to the small
intestine, the large intestine may also be important for the
absorption of xenobiotics, especially oral drugs formulated for
sustained release6. The bacteria in the large intestine contain
various enzymes that metabolize xenobioitcs as well as endogen-
ous chemicals such as bile acids and dietary constituents7,8. In
addition, colon-speciﬁc oral drug-delivery systems have been
utilized recently to administer a variety of therapeutic agents9.
Therefore, it is important to determine the regulation of xenobiotic
biotransformation in the intestine.
The drug-processing genes involved in the xenobiotic biotrans-
formation include various phase-I and phase-II drug metabolizing
enzymes, as well as uptake and efﬂux transporters. In general, the
content of DPGs is lower in intestine than that in liver10. DPGs
play a critical role in the absorption, metabolism, disposition,
elimination and detoxiﬁcation of xenobiotics and other drugs11.
Phase-I enzymes catalyze hydrolysis, reduction, and oxidation of
drugs. The cytochrome P450s (CYPs) in the ﬁrst 3 families are
among the most important phase-I enzymes that contribute to the
biotransformation of the majority of xenobiotics, whereas the
CYP4 family members are important for fatty acid metabolism.
The NAD(P)H dehydrogenase, quinone 1 (Nqo1) is involved in
reduction reactions, and it is a prototypical target gene of the
oxidative stress sensor nuclear factor erythroid 2-related factor 2
(NRF2). Aldehyde dehydrogenases (ALDHs) are important phase-
I enzymes for the detoxiﬁcation of aldehydes, which are the
metabolites of alcohols. Phase-II metabolism refers to the con-
jugation reactions that generally increase the water-solubility of
substrates to form more polar compounds with exceptions. The
three major classes of phase-II enzymes include UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs), as
well as glutathione S-transferases12. Whereas some drugs diffuse
into the intestinal cells, there are two major classes of transporters,
namely the solute carriers (SLC) and ATP-binding cassette (ABC)
transporters, that are important in the disposition of many
large and/or polar chemicals. Intestinal transporters mediate thetranslocation of chemicals in and out of enterocytes, and this
process is important for drug disposition in the body13.
DPGs can be trans-activated by various nuclear receptors
following xenobiotic exposure. The constitutive androstane receptor
(CAR/Nr1i3) is one of the important xenobiotic-sensing nuclear
receptors that regulate the transcription of DPGs. CAR is activated
by various chemicals including steroid hormones, bile acids,
pharmaceuticals, as well as environmental, dietary, and occupational
chemicals14, via direct or indirect mechanisms. Direct activation of
CAR refers to ligand-binding to the CAR protein, and the
prototypical CAR ligands include TCPOBOP for the mouse CAR
and CITCO for the human CAR. The indirect activation of CAR by
chemicals such as phenobarbital disassociates CAR from its
cytosolic repressor protein. CAR activation leads to its nuclear
translocation and binding to the targeted response elements of
genes, and this usually leads to the transcriptional up-regulation of
DPGs. Chronic activation of CAR is known to cause liver tumor in
rodents but to a much lesser extent in humans15,16. Pharmacological
activation of CAR by TCPOBOP has also been shown to reduce
obesity in mice17. Car / mice have been engineered to determine
the necessity of CAR in xenobiotic metabolism and liver physiol-
ogy18. Phenobarbital-mediated up-regulation of the prototypical
CAR-target gene Cyp2b10 does not occur in livers of Car /
mice, and there is also decreased metabolism of the classic CYP
substrate zoxazolamine, as well as a complete loss of the liver
hypertrophic and hyperplastic responses to CAR-inducers.
CAR is highly expressed in liver, but it can also be detected at
high amounts in the small intestine, and a lower amount in the large
intestine19–21. Extensive studies have been done regarding the effect
of CAR-activation on the hepatic DPG expression18,22–24. Despite
the important role of the intestine in xenobiotic biotransformation,
relatively less is known regarding the effect of genetic depletion of
Car and the pharmacological activation of CAR on the basal and
inducibility of DPGs in different sections of intestine. Therefore, the
goal of this study was to determine whether the well-known CAR-
targeted DPGs in liver are also regulated by CAR in duodenum,
jejunum, ileum, and colon.
2. Materials and methods
2.1. Chemicals and reagents
The mouse CAR ligand 1,4-bis-[2-(3,5-dichloropyridyloxy)]ben-
zene (3,30,5,50-tetrachloro-1,4-bis(pyridyloxy)benzene, TCPO-
BOP) and corn oil were purchased from Sigma–Aldrich (St.
Louis, MO, USA).
2.2. Animal procedures
C57BL/6 wild-type (WT) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Breeder pairs of the Car /
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(Thousand Oaks, CA, USA). Mice were housed according to the
American Animal Association Laboratory Animal Care Guide-
lines, and were bred under standard conditions at the University of
Washington (WA, USA). All animals were given ad libitum access
to water and irradiated Picolab Rodent Diet 20 number 5053 (PMI
Nutrition International, Brentwood, MO, USA). Sixty-day-old
wild type and Car / male mice were administered the CAR-
ligand TCPOBOP (3 mg/kg, i.p.), or vehicle, once daily for 4 days
(n¼4–5 per group). Various sections of intestine (duodenum,
jejunum, ileum, and colon) were collected on the 5th day. The
tissues were frozen immediately in liquid nitrogen and then stored
in a –80 1C freezer prior further analysis. All animal procedures
were approved by the Institutional Animal Care and Use Com-
mittee at the University of Washington.
2.3. RNA isolation
Total RNA was isolated from each section of frozen intestine
tissues using RNA zol Bee reagent (Tel-Test Inc., Friendswood,
TX, USA) directed by the manufacturer's protocol. The total RNA
concentration of each sample was quantiﬁed spectrophotometri-
cally at 260 nm using a NanoDrop 1000 Sectrophotometer
(Thermo Scientiﬁc, Waltham, MA, USA). The RNA integrity of
each sample was evaluated by formaldehyde agarose gel electro-
phoresis, and assured by appearance of 18S and 28S rRNA bands.
2.4. Reverse transcription and quantitative polymerase chain
reaction (RT-qPCR)
Total RNA was reverse-transcribed to cDNA by High-Capacity
cDNA Reverse Transcription Kits 1001073 (Applied Biosystems,
Foster, CA, USA) in a ﬁnal volume 10 mL containing 5 mL of RNA
sample and 5 mL of 2RT master mix directed by the manufac-
turer's protocol. The cDNAs were diluted 10 times and ampliﬁed by
PCR, using the SsoAdvanced Universal SYBR Green Supermix in a
Bio-Rad CFX384 Real-Time PCR Detection System (Bio-rad,
Hercules, CA, USA). Two mL of cDNA were added to 8 mL of
PCR mix, containing SsoAdvanced Universal SYBR Green Super-
mix (2 ), forward and reverse primers, and nuclear-free water. The
primers for PCR were designed using the NCBI Primer Design Tool
as shown in Table 1, and were purchased from the Integrated DNA
Technologies (Coralville, IA, USA). Data were expressed as
percentage of the housekeeping gene β-actin.
2.5. Western blotting analysis
Each section of intestinal homogenate was prepared using 250 mL
ST buffer (250 mmol/L sucrose, 10 mmol/L Tris base, pH 7.5)
with protease inhibitors. The crude membranes were prepared
from each section of frozen intestine samples as described
previously25. The protein concentrations in each section of
intestines were determined by a Qubit Protein Assay Kit (Thermo
Fisher Scientiﬁc, Grand Island, NY, USA) as directed by the
manufacturer's instructions. The samples were subjected to poly-
acrylamide gel electrophoresis and transferred onto a polyvinyli-
dene diﬂuoride (PVDF) membrane for 3 h on the ice. After
transfer, the membranes were blocked by 5% nonfat dry milk in
phosphate-buffered saline with 0.05% Tween 20 (PBST) for 1 h
and incubated overnight with the following primary antibodies
diluted in 1% dry milk in PBST: rabbit anti-mouse CYP2B10polyclonal antibody (AB9916, 1:5000, EMD Millipore); or goat
anti-mouse H3 polyclonal antibody (ab12079, 1:500, Abcam).
After washing with 1% dry milk in PBST, the membranes were
incubated for 1 h with a 1:2000 HRP-linked species-appropriate
secondary antibody (Sigma Aldrich, St. Louis, MO, USA) diluted
in 1% dry milk in PBST. After incubation, the membranes were
washed again with 1% dry milk in PBST and then with 1% PBS,
followed by incubation in Novex ECL Chemiluminescent Sub-
strate Reagent Kit (Life Technologies, Carlsbad, CA, USA).
2.6. Statistical analysis
For RT-qPCR analysis, data among multiple groups were analyzed
using analysis of variance (ANOVA) followed by the Duncan's
post hoc test (Po0.05) using the SPSS software (IBM Coopera-
tion, Armonk, North Castle, NY, USA). Asterisk (*) indicates
statistically signiﬁcant differences between control and
TCPOBOP-treated wild-type mice. Pound sign (#) indicates
statistically signiﬁcant differences (Po0.05) between control and
TCPOBOP-treated Car / mice. Dollar sign ($) indicates sig-
niﬁcant differences (Po0.05) in the basal mRNA expression of
DPGs between control WT and control Car / mice. Protein
density was quantiﬁed using Image J Software (National Institutes
of Health, Bethesda, MD, USA).3. Results
3.1. DPG expressions in intestine
BioGPS26 data were examined to determine which DPSs are
highly expressed in the small and large intestine (Fig. 1). Those
DPGs that were expressed in the intestine were selected (Table 2)
to examine their mRNA expression in response to the CAR-ligand
TCPOBOP in intestine, based on the following selection criteria:
(1) the DPGs have been shown to be bona ﬁde CAR-target genes
in mouse liver24, or (2) the DPGs that were not examined in liver24
but are highly expressed in small or large intestine (http://biogps.
org/)26,27.
The relative mRNA abundance of the major DPG families in
the small and large intestine are shown in Fig. 1. Data were
retrieved from BioGPS as described above. For the Cyp1 family,
Cyp1a1 appeared to be the major intestinal Cyp1 isoform and its
mRNA was much higher in small intestine than that in large
intestine. Cyp1a2 mRNA was minimally expressed in intestine
(Fig. 1a), although it was shown to be the major Cyp1 isoform in
liver28. Cyp1b1 was expressed at low levels and it was also small
intestine-enriched. For the Cyp2b family, Cyp2b10 was the only
isoform that was expressed in intestine, and its mRNA was
predominantly found in the small intestine but not in large
intestine (Fig. 1b). For the Cyp3a family, the mRNAs of Cyp3a11,
3a13, and 3a25 were highly expressed in small intestine; Cyp3a13
mRNA was also detected at low levels in the large intestine,
whereas other Cyp3a isoforms (including Cyp3a16, 3a41a, and
3a44) were not expressed in intestine (Fig. 1c). For the Cyp4
family, Cyp4b1 was the major intestinal isoform in both small and
large intestine. Cyp4a10 and 4a31 mRNAs were also detected at
low levels in the large intestine, whereas they were minimally
expressed in the small intestine. Other Cyp4 isoforms (including
Cyp4a12a and 4a14) were minimally expressed in intestine
(Fig. 1d). The Nqo1 mRNA appeared to be higher than Nqo2
mRNA in both small and large intestines (Fig. 1e). For the Aldh
Table 1 RT-qPCR primer sequences
Gene Symbol Forward Reverse  
Cyp1a1 GGCCACTTTGACCCTTACAA CAGGTAACGGAGGACAGGAA 
Cyp2b10 AAGGAGAAGTCCAACCAGCA CTCTGCAACATGGGGGTACT 
Cyp3a11 ACAAACAAGCAGGGATGGAC GGTAGAGGAGCACCAAGCTG 
Cyp3a13 AAGTACTGGCCAGAGCCTGA AATGCAGTTCCTTGGTCCAC 
Cyp3a25 GCCTTGCTTCAAACCAGAAG CATCATAGCCCCCGAAGATA 
Cyp4a10  CACACCCTGATCACCAACAG TCCTTGATGCACATTGTGGT 
Cyp4b1 CTGCATGGCCCTTTATCCTA GAAGCACTCCTTCATGCACA 
Nqo1 TATCCTTCCGAGTCATCTCTAGCA TCTGCAGCTTCCAGCTTCTTG 
Aldh1a1 CTCTGTTCCCCAGGTGTTGT CATGCAAGGGTGCCTTTATT 
Aldh1a7 TGCTATTTGGCTGTCCCTGT ACCATGTTCGCCCAGTTCTC 
Aldh1b1 TTGAACGAATCCTGGGCTAC CCGAAGACTGTGGGTTTGAT 
Aldh3a2 CACCACCCAAAGTCTGTGTG AAGATGCTCTGAGTGGCCTT 
Aldh3b1 CCCAACCTGGGCAGAATCAT GTAGCGCTCTCCCTCATCAC 
Aldh9a1 AGCTGAAGACGGTGTGTGTG CCCAAAGCCTGGATGTAAGA 
Sult1a1 GGATGTAGCTGAGGCAGAGG CAGCTCCCAGTGGCATTTAT 
Sult1b1 GGTGGGAAAAGAGGGAAGAG AAGGCCTCTTCATCCAAGGT 
Sult1c2 GACCCCAGAACTGAGCAGAC AGCTGGCATCTCATTGGCTT 
Sult1d1 GCCGTCTCCTCGAATAGTGA TTCCCACCAGCTCTTCACAT 
Sult2b1 AAGGCATTCTTCAGCTCCAA GAAGGAACTGGTCGGGTGTA 
Sult5a1 CCAGTCCAAGATGGGTGACT AGACCAGGGTTGTAGCATGG 
Papss2 ACCTTGGAGACCGAAGGTTT TTCTTGGCAACAATGAACCA 
Gsta1 CGCCACCAAATATGACCTCT TTGCCCAATCATTTCAGTCA 
Gsta2 AGCCCGTGCTTCACTACTTC CAATCTCCACCATGGGCACT 
Gsta4 TGATGATGATTGCCGTGGCT ACGAGAAAAGCCTCTCCGTG 
Gstt1 CTTGCTCTACCTGGCACACA CTTCTCCGAAGGCCCGTATG 
Gstt2 ACTAAGGTCCTGGGCTGGAT TGGATAGCTGACACCTGCTG 
Gstt3 TCCAGCTGCGTACCATAGAG ACACTCTCTGCCAAGACGAA 
Gstm1 CTCCCGACTTTGACAGAAGC TTGCTCTGGGTGATCTTGTG 
Gstm2 ATGGTTTGCAGGGAACAAGGT CTTCAGGCCCTCAAAGCGAC 
Gstm3 AGAGGAGGAGAGGATCCGTG GGGACTGCAGCAGACTATCAT 
Gstm4 TATGACACTGGGTTACTGGGACATC TCCACGCGAATCTTCTCTTCC 
Gstm5 GGTTTGCAGGAGAAAAGCTG CCTTCAGGTTTGGGAACTCA 
Ugt1a1 CACCTGAAGCCTCAATACCAT CAGTCCGTCCAAGTTCCACC 
Ugt1a9 CTGGTTCAGCCAGAGGTTTC TTGGCGACAATTAATCCACA 
Ugt2b34 AGCTGCCAAAGCAGTCATTT GCCAGGATCACATCAAACCT 
Ugt2b35 GCTCAACTGCTCCAGATTCC GGCCACCTAATCCTGACAAA 
Ugt2b36 TGTGGGAAGGTGTTGGTATGG TCCACAGCCTTTGCAAAAATAA 
Oatp2a1  GGTGCCCATTCAGCCATTTG GTGTCCACTCTGCCGTAGTC 
Asbt TGGAATGCAGAACACTCAGC GCAAAGACGAGCTGGAAAAC 
Mrp2 TCCTAGACAGCGGCAAGATT GCTAGAGCTCCGTGTGGTTC 
Mrp3 TGGTCATGCTGTCAGCTTTC AAGGACTGAGGGGAACGAAT 
Mrp4 GCAAAGCCCATGTACCATCT ACCACGGCTAACAACTCACC 
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Figure 1 Expression of drug processing genes (DPGs) in small and large intestine of mice. The mRNA abundance of DPGs was retrieved from
BioGPS (Biogps.org, Su et al.26). The abundance of DPGs was expressed as average probe intensity from the microarray data in BioGPS. DPGs
that were highly expressed in at least one section of intestine and/or are known as CAR-target genes (Aleksunes and Klaassen24) in liver were
selected for the analysis (n¼2 per tissue). For each graph, black bar represents DPG expression in the small intestine whereas red bar represents
DPG expression in the large intestine.
Regulation of drug-processing genes in intestine by CAR 479family, Aldh1a1, 1b1, and 9a1 were the predominant isoforms and
in general, they were more highly expressed in small intestine than
in large intestine. Aldh1a7, 1l1, 3a2, and 6a1 were also expressed
at low levels in both the small and large intestine, Aldh16a1 and
18a1 were lowly expressed in small intestine but minimally
expressed in large intestine, whereas other Aldh isoforms (includ-
ing Aldh1a2, 1a3, 1l2, 2, 3a1, 3b1, 3b2, 4a1, 5a1, 7a1, and 8a1)
were minimally expressed in small and large intestine (Fig. 1f).
For the Gsta family, Gsta1 appeared to be the major intestinal
isoform and its mRNA was much higher in small intestine than in
large intestine. Gsta4 mRNA was also detected at low levels in
both small and large intestine. Gsta2 and Gsta3 were minimally
expressed in intestine (Fig. 1g). For the Gstm family, Gstm1, 2,
and 5 were highly expressed in large intestine; Gstm1, 2, 3, and 5
were also detected at low levels in small intestine, whereas other
Gstm isoforms (including Gstm4, m6, and m7) were minimally
expressed in small and large intestine (Fig. 1h). For the Gstt
family, Gstt1, 2, and 3 mRNAs were the predominant isoforms in
both small and large intestine, whereas Gstt4 was minimally
expressed in small and large intestine (Fig. 1i). For the Sult family,
Sult1b1, 1d1, and 2b1 appeared to be highly expressed in small
intestine with the mRNA abundance in descending order; Sult1b1
and 1d1 were also expressed at high levels in the large intestine.Sult1a1 was only expressed in large intestine but not in small
intestine, and its mRNA was highly enriched in the large intestine.
Sult1c2 and 2b1 were also lowly expressed in the large intestine.
Other Sult isoforms (including Sult1e1, 2a2, 3a1, 4a1, 5a1, and
6b1) were minimally expressed in small and large intestine
(Fig. 1j). For the Ugt family, Ugt1a transcripts (note: probes were
not speciﬁc to differentiate various Ugt1a isoforms) and Ugt2b34
mRNA appeared to be the major Ugt genes expressed in small and
large intestine. Ugt1a transcripts were more highly expressed in
large intestine than small intestine. Ugt2b5 and 2b35 were lowly
expressed in both small and large intestines. Ugt2a3 was detected
at low levels only in the small intestine, whereas Ugt2b38 and 3a2
were expressed at low levels only in large intestine. Other Ugt
isoforms were minimally expressed in intestine (Fig. 1k).
For the Solute carrier organic anion (Slco) transporter family
(also known as the Oatps), Slco2a1, 2b1, 3a1, and 4a1 were the
intestine-enriched Slco isoforms and they were more highly
expressed in small than in large intestine. Other Slco isoforms
(including Slco1a1, 1a4, 1a5, 1a6, 1b2, 1c1, 5a1, 6b1, 6c1, and
6d1) were not expressed in intestine (Fig. 1I). For the Abcc family
(Mrp), Abcc3 appeared to be the major intestinal isoform and its
mRNA was approximately twice in large intestine as that in small
intestine. Abcc1 was detected at low levels in large intestine,
Table 2 Liver and Intestine regulation difference in Car-null control mice compared to WT control mice.
Basal expression of genes is shown as increased or decreased relative to that in Car-null mice. Up-regulation suggests CAR suppresses the basal expression of
the gene and down-regulation suggests CAR is necessary in maintaining the constitutive expression of the gene.
n Note: The liver data were obtained from Aleksunes and Klaassen24, 2012.
Shinhee Park et al.480
Figure 3 Messenger RNA expression of phase-I drug-metabolizing en
(duodenum, jejunum, ileum, and colon) of WT and Car / male mice treat
are expressed as percentage of the housekeeping gene β-actin (n¼4–5 pe
followed by Duncan's post hoc test. Asterisks (*) indicate statistically sig
treated WT mice at the same section of intestines. Pound signs (#) indicate
and with TCPOBOP-treated Car / mice. Dollar signs ($) indicate statist
between control WT and control Car / mice.
Figure 2 Messenger RNA expression of Car in mice liver and
intestine. The Car mRNA in liver and various sections of the intestine
was quantiﬁed using RT-qPCR as described in Section 2 (WT mice
only). Data are expressed as percentage of the housekeeping gene β-
actin (n¼4–5 per group). Data between control and TCPOBOP-
treated groups were analyzed using a Student's t-test. Asterisks (*)
indicate statistically signiﬁcant differences (Po0.05) between control
and TCPOBOP-treated WT mice in the same tissue.
Regulation of drug-processing genes in intestine by CAR 481whereas Abcc2 was detected at low levels in small intestine.
Abcc4, 5, 9, and 10 were also expressed at low levels in both small
and large intestine. Other Abcc isoforms (including Abcc6, c8, and
c12) were not detected in the intestine (Fig. 1m).
In summary, BioGPS has identiﬁed distinct DPG isoforms that
are expressed in the intestine. Based on this information, as well as
the previous ﬁndings regarding known CAR-targeted DPGs in
liver24, DPGs listed in Table 2 were selected for the induction
studies in WT and Car / mice.
Previously, it has been shown that CAR is highly expressed in
liver24, and the basal expression of CAR was also found at
relatively high levels in various sections of intestine19,21. To
further determine the distribution of CAR in intestine as compared
to liver in control and TCPOBOP-treated conditions, and to
conﬁrm the depletion of Car in intestine of the Car / mice,
the Car mRNA was quantiﬁed in various sections of intestine and
liver from WT and Car / mice treated with corn oil or
TCPOBOP (Fig. 2). CAR was most highly expressed in liver of
the WT mice, followed by duodenum and jejunum, whereas ileum
and colon had very low levels of Car expression. TCPOBOP
down-regulated the Car mRNA in liver and duodenum of WT
mice, and tended to decrease in jejunum, although a statistically
signiﬁcant difference was not achieved. As expected, the Carzymes, including Cyp1–4 and Nqo1 in various sections of intestine
ed with vehicle (corn oil) or TCPOBOP as described in Section 2. Data
r group). Data among multiple groups were analyzed using ANOVA
niﬁcant differences (Po0.05) between control WT and TCPOBOP-
statistically signiﬁcant differences (Po0.05) between control Car /
ically signiﬁcant differences (Po0.05) of the basal mRNA expression
Figure 4 Messenger RNA expression of the phase-I drug-metabolizing enzymes Aldhs in various sections of intestine (duodenum, jejunum,
ileum, and colon) of WT and Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in Section 2. Data are expressed as
percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA followed by Duncan's
post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-treated WT mice at the same
section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car / and with TCPOBOP-treated
Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression between control WT and
control Car / mice.
Shinhee Park et al.482mRNA was not expressed in any of the tissues examined in the
Car / mice.
3.2. Regulation of phase-I drug metabolizing enzymes (Cyps and
Aldh) in intestine by CAR
The expressions of selected phase-I enzymes are shown in
Figs. 3 and 4. For Cyps (Fig. 3a–g), the basal expression of Cyp1a1
was highest in duodenum, followed by jejunum and ileum, and was
minimal in colon. Interestingly, in control Car / mice, the basal
Cyp1a1 mRNA increased 11.97-fold in duodenum and 6.02-fold in
jejunum, suggesting that CAR suppresses the basal expression of
Cyp1a1 in duodenum and jejunum of WT mice. TCPOBOP did not
alter Cyp1a1 mRNA in any portions of the intestine in WT mice;
however, it down-regulated Cyp1a1 89.3% in duodenum of the
Car / mice, suggesting an off-target effect of TCPOBOP inde-
pendent of CAR (Fig. 3a). Regarding the prototypical CAR-target
gene Cyp2b10, as shown in Fig. 3b, the basal expression of Cyp2b10
was the highest in duodenum followed by jejunum, but was
minimally expressed in ileum and colon. In Car / mice, the
basal Cyp2b10 mRNA increased in colon (22.1-fold) but the
expression was still minimal. TCPOBOP up-regulated Cyp2b10
mRNA 4.98-fold in duodenum, 5.72-fold in jejunum, and 20.2-fold
in ileum of WT mice in a CAR-dependent manner. As shown in
Fig. 3c, the basal expression of Cyp3a11 was highest in duodenum,
followed by jejunum, ileum, and colon. In Car / mice, basal
Cyp3a11 mRNA decreased 55% in jejunum and 75% in ileum,
suggesting that CAR is necessary for the basal expression of
Cyp3a11 in these sections. TCPOBOP up-regulated Cyp3a11expression 70% in duodenum in a CAR-dependent manner. How-
ever, it did not alter the Cyp3a11 mRNAs in other sections of the
intestine. As shown in Fig. 3d, the basal expression of Cyp3a13 was
highest in duodenum, followed by jejunum, and was much lower in
ileum and colon. In Car / mice, the basal Cyp3a13 mRNA
expression decreased 60% in duodenum, suggesting that CAR is
necessary in maintaining the constitutive expression of Cyp3a13 in
the duodenum. TCPOBOP up-regulated Cyp3a13 mRNA expression
38% in duodenum and 44% in jejunum in a CAR-dependent
manner; however, it did not alter Cyp3a13 mRNA in ileum or
colon. As shown in Fig. 3e, the basal expression of Cyp3a25 was
highest in duodenum, followed by jejunum and ileum but was
minimal in colon. In Car / mice, the basal Cyp3a25 mRNA
decreased in duodenum (77.8%), jejunum (58.4%), and ileum
(59.6%), suggesting that CAR is necessary for the basal expression
of Cyp3a25 in the small intestine. TCPOBOP in general did not alter
the Cyp3a25 mRNA expression in any sections of intestine. As
shown in Fig. 3f, the basal expression of Cyp4a10 was the highest in
duodenum, followed by colon, jejunum, and ileum. TCPOBOP in
general did not alter the expression of Cyp4a10, except for a down-
regulation (63.5%) in ileum in a CAR-dependent manner. As shown
in Fig. 3g, the basal expression of Cyp4b1 was similarly expressed in
all portions of the intestine. In Car / mice, the basal Cyp4b1
mRNA decreased 34% in duodenum, 71% in ileum and 81% in
colon, suggesting that CAR is necessary in maintaining the basal
expression of Cyp4b1 in these sections. TCPOBOP down-regulated
Cyp4b1 mRNA expression 27.4% in ileum of WT mice. As shown
in Fig. 3h, the basal expression of Nqo1 was highest in colon,
followed by duodenum, ileum, and jejunum. In Car / mice, the
Figure 5 Messenger RNA expression of the phase-II drug-metabolizing enzymes Sults in various sections of intestine (duodenum, jejunum,
ileum, and colon) of WT and Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in Section 2. Data are expressed as
percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA followed by Duncan's
post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-treated WT mice at the same
section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car / and with TCPOBOP-treated
Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression between control WT and
control Car / mice.
Regulation of drug-processing genes in intestine by CAR 483basal Nqo1 mRNA increased 1.09-fold in jejunum, suggesting that
CAR suppresses the basal expression of Nqo1 in WT mice intestine.
TCPOBOP moderately down-regulated Nqo1 27.1% in ileum of the
Car / mice. In summary, CAR suppresses the basal expression of
Cyp1a1 and Nqo1, but maintains the constitutive expression of
Cyp3a11, Cyp3a13, Cyp3a25, and Cyp4b1, in distinct sections of
intestine; whereas pharmacological activation of CAR by TCPOBOP
up-regulates Cyp2b10, Cyp3a13, Cyp3a13, but down-regulates
Cyp4a10 and Cyp4b1 in distinct sections of intestine, in a CAR-
dependent manner.
Regarding the regulation of the aldehyde dehydrogenases
(Aldhs), as shown in Fig. 4a, the basal expression of Aldh1a1
was highest in colon and duodenum, followed by jejunum, and
ileum. In Car / mice, the basal Aldh1a1 mRNA moderately
decreased 54% in ileum. TCPOBOP up-regulated Aldh1a1
mRNA 5.37-fold in duodenum and 87% in jejunum in a CAR-
dependent manner. However, TCPOBOP did not alter the
Aldh1a1 mRNA expression in ileum and colon. As shown in
Fig. 4b, the basal expression of Aldh1a7 was highest in ileum,
followed by colon, jejunum, and minimal in duodenum. The
absence of CAR leads to an apparent increase in Aldh1a7 in
duodenum and jejunum, although a statistical signiﬁcance wasnot achieved. TCPOBOP up-regulated Aldh1a7 mRNA 51.4-fold
in duodenum and 5.00-fold in jejunum in a CAR-dependent
manner, but it slightly decreased Aldh1a7 mRNA in colon. As
shown in Fig. 4c, the basal expression of Aldh1b1 was relatively
similar in all portions of the intestine. In Car / mice, the basal
expression of Aldh1b1 mRNA was 70.9% higher in jejunum and
57.4% in colon than in WT mice, and TCPOBOP did not alter
Aldh1b1 mRNA in any intestinal sections. As shown in Fig. 4d,
the basal expression of Aldh3a2 was relatively similar in all
portions of intestine. In Car / mice, basal Aldh3a2 mRNA
decreased 41.6% in duodenum and 65.6% in ileum. TCPOBOP
did not have any effect on the Aldh3a2 mRNA expression in
intestine. As shown in Fig. 4e, the basal expression of Aldh3b1
expression was highest in colon and ileum, and was minimal in
duodenum and jejunum. Interestingly, In Car / mice, the
basal Aldh3b1 mRNA markedly increased 124.7-fold in duode-
num and 26.8-fold in jejunum, which suggest that CAR
suppresses the basal expression of Aldh3b1 in WT mice intestine.
TCPOBOP up-regulated Aldh3b1 expression 160.4-fold in duo-
denum, 20.9-fold in jejunum, and 41.9% in ileum in a CAR-
dependent manner. As shown in Fig. 4f, the basal expression of
Aldh9a1 decreased from duodenum to colon. TCPOBOP did not
Figure 6 Messenger RNA expression of the phase-II drug-metabolizing enzymes Gstas and Gstts in various sections of intestine (duodenum,
jejunum, ileum, and colon) of WT and Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in Section 2. Data are
expressed as percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA
followed by Duncan's post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-
treated WT mice at the same section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car /
and with TCPOBOP-treated Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression
between control WT and control Car / mice.
Figure 7 Messenger RNA expression of the phase-II drug-metabolizing enzymes Gstms in various sections of intestine (duodenum, jejunum,
ileum, and colon) of WT and Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in Section 2. Data are expressed as
percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA followed by Duncan's
post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-treated WT mice at the same
section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car / and with TCPOBOP-treated
Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression between control WT and
control Car / mice.
Shinhee Park et al.484
Figure 8 Messenger RNA expression of the phase-II drug-metabolizing enzymes Ugts in various sections of intestine (duodenum, jejunum,
ileum, and colon) of WT and Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in Section 2. Data are expressed as
percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA followed by Duncan's
post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-treated WT mice at the same
section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car / and with TCPOBOP-treated
Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression between control WT and
control Car / mice.
Regulation of drug-processing genes in intestine by CAR 485alter the Aldh9a1 mRNA expression in any portions of intestine.
In summary, CAR suppresses the basal expression of Aldh3b1
but maintains the constitutive expression of Aldh1a1, Aldh1b1,
and Aldh3a2 in distinct sections of intestine, whereas pharma-
cological activation of CAR by TCOBOP up-regulates Aldh1a7
and Aldh3b1 in a CAR-dependent manner in distinct sections of
small intestine.3.3. Regulation of phase-II drug metabolizing enzymes (Sult,
Gsta, Gstt, Gstm, Ugt) in intestine by CAR
Figs. 5–8 illustrate the regulation of various phase-II enzymes by
CAR in intestine. Regarding the regulation of Sult, as shown in
Fig. 5, the basal Sult1a1 mRNA expression was predominantly
expressed in colon, and was very lowly expressed in all portions of
the small intestine. TCPOBOP did not alter the expression of
Sult1a1 mRNA in any portions of intestine (Fig. 5a). As shown in
Fig. 5b, the basal expression of Sult1b1 mRNA was highest in
duodenum, followed by jejunum, colon, and ileum. In Car /
mice, there was a decrease in the basal Sultb1 mRNA in duodenum
(47.1%), but an increase in the basal Sult1b1 mRNA in colon
(61.2%). TCPOBOP did not alter the Sult1b1 mRNA expression in
any portions of intestine. As shown in Fig. 5c, the basal mRNA
expression of Sult1c2 is highest in colon, followed by ileum and
jejunum, and was minimally expressed in duodenum. In Car /
mice, the basal Sult1c2 mRNA expression was 60% lower in
ileum, suggesting that CAR is necessary in maintaining constitu-
tive expression of Sult1c2 in ileum of WT mice. TCPOBOP up-
regulated Sult1c2 mRNA 73.6-fold in duodenum and 4.8-fold in
jejunum in a CAR-dependent manner. However, TCPOBOP did
not alter Sult1c2 mRNA expression in ileum or colon. As shown inFig. 5d, the basal mRNA expression of Sult1d1 increased from
duodenum to colon. In Car / mice, the basal Sult1d1 mRNA
increased 23.9-fold and 6.21-fold in duodenum and jejunum;
however, it decreased 75.8% in ileum and 74.4% in colon.
TCPOBOP up-regulated Sult1d1 mRNA 52.4-fold in duodenum
and 12.5-fold in jejunum in a CAR-dependent manner, whereas it
had no effect on the Sult1d1 mRNA in ileum, and down-regulated
47.5% in colon of WT mice. As shown in Fig. 5e, the basal
expression of Sult2b1 mRNA decreased from duodenum, to colon.
In Car / mice, the basal Sult2b1 mRNA decreased in duodenum
(53.1%) but increased in colon (1.31-fold). TCPOBOP down-
regulated Sult2b1 mRNA 61.4% in duodenum, but had no effect in
other portions of the intestine. As shown in Fig. 5f, the basal
expression of Sult5a1 was highest in colon and duodenum, and
lower in ileum, and jejunum. TCPOBOP had minimal effect on
Sult5a1 mRNA expression, except for a moderate increase
(57.4%) in jejunum in a CAR-dependent manner. As shown in
Fig. 5g, the basal mRNA expression of Papss2 was highest in
duodenum and colon, but was much lower in jejunum and ileum.
TCPOBOP did not have any effect on Papss2 mRNA expression
in any portions of intestine of either genotype.
Regarding the Gsta, as shown in Fig. 6a–c, the basal mRNAs of
multiple Gsta family members (Gsta1, 2, and 4) followed a similar
expression pattern, which was highest expression in duodenum,
followed by jejunum, and minimal expression in ileum and colon.
In duodenum, TCPOBOP up-regulated the mRNAs of Gsta1
(1.46-fold), Gsta2 (4.56-fold), and Gsta4 (2.45-fold) in a CAR-
dependent manner (Fig. 6a–c). In jejunum, TCPOBOP also up-
regulated Gsta2 mRNA 1.72-fold in a CAR-dependent manner.
However, TCPOBOP had no effect on the Gsta expression in other
portions of intestine in either WT or Car / mice (Fig. 6a–c).
Regarding the Gstt, as shown in Fig. 6d, Gstt1 mRNA basal
Figure 9 Messenger RNA expression of the transporters in various sections of intestine (duodenum, jejunum, ileum, and colon) of WT and
Car / male mice treated with vehicle (corn oil) or TCPOBOP as described in the Section of materials and methods. Data are expressed as
percentage of the housekeeping gene β-actin (n¼4–5 per group). Data among multiple groups were analyzed using ANOVA followed by Duncan's
post hoc test. Asterisks (*) indicate statistically signiﬁcant differences (Po0.05) between control WT and TCPOBOP-treated WT mice at the same
section of intestines. Pound signs (#) indicate statistically signiﬁcant differences (Po0.05) between control Car / and with TCPOBOP-treated
Car / mice. Dollar signs ($) indicate statistically signiﬁcant differences (Po0.05) of the basal mRNA expression between control WT and
control Car / mice.
Shinhee Park et al.486expression was highest in duodenum, followed by colon, jejunum,
and ileum, and was not readily altered by TCPOBOP in any
portions of intestine, except for a moderate increase by TCPOBOP
in ileum of WT mice. CAR deﬁciency moderately decreased the
basal Gstt1 mRNA in ileum (27.8%). As shown in Fig. 6e, the
basal expression of Gstt2 mRNA was highest in colon, followed
by duodenum, ileum, and jejunum, and was not altered by
TCPOBOP in any intestinal sections. As shown in Fig. 6f, the
basal expression of Gstt3 was low in duodenum and jejunum, but
was much higher in ileum and highest in colon. CAR deﬁciency
resulted in a 34.5-fold up-regulation of Gstt3 mRNA in duodenum
and a 10.2-fold in jejunum of WT mice. Interestingly, TCPOBOP
also up-regulated Gstt3 mRNA in these two sections (47.4-fold
and 9.34-fold, respectively) in a CAR-dependent manner, whereas
it did not have any effect in ileum and colon. Regarding the Gstm
family members (Fig. 7a–e), the basal mRNA expression of Gstm1
(Fig. 7a), Gstm4 (Fig. 7d), and Gstm5 (Fig. 7e) was highest in
duodenum, followed by colon, jejunum, and ileum; the basal
mRNA expression of Gstm2 was highest in colon, followed by
duodenum, ileum, and jejunum; whereas the basal mRNA expres-
sion of Gstm3 was highest in duodenum, followed by jejunum,
colon, and ileum (Fig. 6d–g). In Car / mice, the basal Gstm3
mRNA decreased 67.0% in ileum, but Gstm5 mRNA increased
58.4% in colon. TCPOBOP up-regulated all Gstm genes, except
for Gstm5, in duodenum (15.8-fold, 6.28-fold, 5.27-fold, and 5.07-
fold, respectively) and jejunum (6.20-fold, 3.65-fold, 3.17-fold,
and 3.16-fold, respectively), in a CAR-dependent manner. In
ileum, TCPOBOP also moderately up-regulated certain Gstm
genes, such as Gstm1 (58%) and Gstm3 (74.7%) in a CAR
dependent manner. TCPOBOP in general had minimal effect on
the Gstm genes in colon of either genotype (Fig. 7a–e). TCPOBOP
moderately down-regulated the Gstm1 and Gstm2 mRNAs inileum, and up-regulated Gstm4 in colon of Car / mice, likely
due to off-target effect of the chemical.
Regarding the regulation of the Ugt family, as shown in Fig. 8a,
the basal mRNA expression of Ugt1a1 was expressed at compar-
able levels in various sections of the intestine. In Car / mice,
there was a moderate decrease in the basal Ugt1a1 mRNA only in
ileum (46.3%). TCPOBOP up-regulated Ugt1a1 mRNA 3.95-fold
in duodenum and 1.46-fold in jejunum in a CAR-dependent
manner. However, TCPOBOP had no effect on the Ugt1a1 mRNA
in ileum or colon. As shown in Fig. 8b, the basal expression of
Ugt1a9 was highest in duodenum, and was lowly expressed in the
other sections of the intestine. The basal Ugt1a9 mRNA was
further decreased in colon of the Car / mice. TCPOBOP in
general did not alter the Ugt1a9 mRNA expression in any sections
of intestine, although it tended to increase the Ugt1a9 mRNA in
duodenum (a statistical signiﬁcance was not achieved). As shown
in Fig. 8c and d, the basal mRNAs of Ugt2b34 and Ugt2b35 were
both highest in duodenum, followed by colon, jejunum, and ileum.
In Car / mice, the basal Ugt2b34 and 2b35 mRNAs decreased
in ileum (50.5% and 40.7%, respectively), suggesting that CAR is
necessary in maintaining constitutive expression of both Ugt2b34
and 2b35. TCPOBOP up-regulated Ugt2b34 mRNA 5.09-fold in
duodenum in a CAR-dependent manner; however, it did not alter
the Ugt2b34 mRNA in other sections of intestine. TCPOBOP had
a similar effect on the Ugt2b35, except that the mRNA increased
in duodenum was not statistically signiﬁcant. As shown in Fig. 8e,
the basal mRNA expression of Ugt2b36 was comparable in
various sections of intestine. In Car / mice, the basal Ugt2b36
mRNA was down-regulated 61.4% in ileum. TCPOBOP up-
regulated Ugt2b36 mRNA 1.65-fold in duodenum and 73.1% in
jejunum in a CAR-dependent manner, however, it did not alter the
Ugt2b36 mRNA in ileum or colon.
Regulation of drug-processing genes in intestine by CAR 487In summary, CAR regulates the basal expression of many
phase-II enzymes in distinct sections of intestine, whereas phar-
macological activation of CAR up-regulates Sult1c2, Sult1d1,
Sult5a1, Gsta1, Gsta2, Gsta4, Gstt3, Gstm1-4, Ugt1a1, Ugt2b34,
Ugt2b36, and tends to up-regulate Ugt1a9 and Ugt2b35, in distinct
sections of intestine in a CAR-dependent manner. In contrast,
pharmacological activation of CAR down-regulates Sult1d1 in
colon and Sult2b1 in duodenum in a CAR-dependent manner;
however, because Car is lowly expressed in colon (Fig. 2), the
TCPOBOP-mediated effects in colon may be due to the involve-
ment of other regulatory factors.3.4. Regulation of the transporters in intestine by CAR
Fig. 9 shows the mRNA expression of uptake and efﬂux
transporters in various sections of intestine of WT and Car /
mice treated with corn oil or TCPOBOP. Regarding the uptake
transporters (Fig. 9a–c), the basal mRNA expression of Oatp2a1
was higher in colon than in the three sections of the small intestine,
and TCPOBOP did not alter the Oatp2a1 mRNA expression in
any sections of intestine, except for a moderate increase in ileum
of Car / mice (46.5%, Fig. 9a). The basal mRNA expression of
Asbt was highest in ileum and colon, but was minimally expressed
in duodenum and jejunum, and TCPOBOP had no effect on the
Asbt mRNA expression in any sections of intestine (Fig. 9b).
Regarding the efﬂux transporters Mrp2–4 (Fig. 9c–e), the basal
mRNA expression of Mrp2 was highest in duodenum, followed by
jejunum, and ileum, but was minimally expressed in colon.
TCPOBOP up-regulated Mrp2 1.93-fold in duodenum, 1.16-fold
in jejunum, and 40.3% in ileum in a CAR-dependent manner. In
Car / mice, TCPOBOP down-regulated Mrp2 mRNA 96.5% in
ileum, but up-regulated Mrp2 mRNA 9.03-fold in colon, which
may be due to off-target effect of the chemical (Fig. 9c). The basal
mRNA expression of Mrp3 was highest in colon, followed by
duodenum, jejunum, and ileum. In Car / mice, the basal Mrp3Figure 10 Western blot analysis of CYP2B10 protein and H3 in
duodenum (small intestine) of wild-type and Car / mice treated with
vehicle (corn oil) or TCPOBOP. Asterisks (*) indicate statistically
signiﬁcant differences (Po0.05) between control WT and TCPOBOP-
treated WT mice in duodenum.mRNA expression was up-regulated 1.18-fold in jejunum and
1.05-fold in ileum, but was down-regulated 48.4% in colon.
TCPOBOP up-regulated Mrp3 mRNA 2.11-fold in duodenum
and 71.9% in ileum in a CAR-dependent manner (it also tended to
increase Mrp3 mRNA in jejunum although a statistically signiﬁ-
cant difference was not achieved). In contrast, TCPOBOP down-
regulated Mrp3 mRNA 50.7% in colon of WT mice. Considering
that Car is minimally expressed in colon (Fig. 2), the TCPOBOP-
mediated down-regulation of Mrp3 may be due to off-target effect
of the chemical (Fig. 9d). The basal mRNA expression of Mrp4
was highest in colon followed by ileum, but was minimally
expressed in duodenum and jejunum. Interestingly, in Car /
mice, there was a marked increase in the basal Mrp4 mRNA in
both duodenum and jejunum (81.1-fold and 15.6-fold, respec-
tively), suggesting CAR suppresses Mrp4 basal expression in these
two sections. Conversely, pharmacological activation of CAR by
TCPOBOP also increased Mrp4 mRNA in duodenum and jejunum
(74.2-fold and 15.4-fold, respectively), in a CAR-dependent
manner. However, TCPOBOP did not alter the Mrp4 mRNA in
ileum and colon (Fig. 9e).
In summary, CAR suppresses the basal expression of Mrp3 in
jejunum and ileum, as well as Mrp4 in duodenum and jejunum,
whereas pharmacological activation of CAR by TCPOBOP has
minimal effect on the uptake transporters but markedly increases
the efﬂux transporters Mrp2–4 in small intestine, but decreases the
Mrp3 mRNA in colon, in a CAR-dependent manner. Even though
Mrp3 and Mrp4 are well known CAR-target genes in liver24 and
intestine (Fig. 9c–e), their basal expressions are highest in colon
where Car is lowly expressed, suggesting that other regulatory
factors are involved in the basal expression of these transporters.
3.5. Regulation of CYP2B10 protein in duodenum by CAR
Because duodenum has the highest Car and Cyp2b10 mRNA
expression (Figs. 2 and 3b), the protein for the prototypical CAR-
target gene Cyp2b10 was quantiﬁed in duodenum of WT and
Car / mice by Western blotting analysis (Fig. 10). Following
TCPOBOP treatment, consistent with the mRNA data, CYP2B10
protein was also increased (5.11-fold) in the duodenum of WT mice
(Fig. 10b). However, such TCPOBOP-mediated induction in the
CYP2B10 protein expression was completely abolished in the
duodenum of Car / mice, suggesting that TCPOBOP-mediated
up-regulation of CYP2B10 protein in duodenum is CAR-dependent.4. Discussion
In conclusion, the present study has demonstrated that in addition to
its important roles in liver24, CAR is also critical in both
maintaining the basal expression of certain DPGs and the pharma-
cological regulation of certain DPGs in a section-speciﬁc manner of
the intestine. A systematic comparison between liver (previous
studies) and intestine (present study) has shown that CAR activation
in liver and intestine produces overlapping but not identical results.
The present study has also compared the section-speciﬁc CAR-
mediated effect on the DPG expression, and has demonstrated that
in general, duodenum appears to be the most responsive section
following exposure to the CAR-ligand TCPOBOP, likely because
CAR is highest expressed in duodenum as compared to other
sections of the intestine. TCPOBOP not only has inducible but also
suppressive effect on the DPG expression in intestine. In addition,
the CAR-independent off-target effect of TCPOBOP has also been
Table 3 Liver and Intestine regulation difference in WT TCPOBOP-treated mice compared to WT control mice.
Cyp1a1 
Cyp2b10 
Cyp3a11 
Cyp3a13 
Cyp3a25 
Cyp4a10 
Cyp4b1 
Nqo1 
Aldh1a1 
Aldh1a7 
Aldh1b1 
Aldh3a2 
Aldh3b1 
Aldh9a1 
Sult1a1 
Sult1b1 
Sult1c2 
Sult1d1 
Sult2b1 
Sult5a1 
Papss2 
Gsta1 S
Gsta2 S
Gsta4 S
Gstm1 S
Gstm2 S
Gstm3 S
Gstm4 S
Gstm5 S
Gstt1 S
Gstt2 S
Gstt3 S
Ugt1a1 
Ugt1a9 
Ugt2b34 
Ugt2b35 
Ugt2b36 
Oatp2a1 
Asbt 
Mrp2 
Mrp3 
Mrp4 
Basal expression of genes is shown as increased or decreased relative to that in wild type mice. (–) denotes none change. N/A: not available.
n Note: The liver data were obtained from Aleksunes and Klaassen24, 2012.
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Regulation of drug-processing genes in intestine by CAR 489observed in the present study, evidenced by TCPOBOP-mediated
changes in DPG expression in Car / mice, and TCPOBOP-
mediated changes in DPG expression in WT colon where CAR is
minimally expressed. Many bona ﬁde CAR-target genes in small
intestine were highest expressed in colon where CAR is minimally
expressed, suggesting that additional regulatory factors are involved
in the basal expression of these genes.
A systematic comparison of the CAR effect on DPG expression
in between liver and various sections of intestine is shown in
Table 2 (CAR-mediated basal expression of DPGs) and Table 3
(effect of pharmacological activation of CAR on the expression of
DPGs). In general, the basal CAR expression is more important for
the constitutive expression of DPGs in intestine rather than in
liver24 (Table 2). Regarding the effect of the pharmacological
activation of CAR, consistent with liver data24, TCPOBOP up-
regulated many DPGs (Cyp2b10, Cyp3a11, Aldh1a1, Aldh1a7,
Gsta1, Gsta4, Gstm1-m4, Ugt1a1, Ugt2b34, Ugt2b36, and Mrp2–
4) in certain portions of the small intestine in a CAR-dependent
manner, with duodenum generally being the most inducible
section. In contrast, Nqo1, Papss2, Ugt1a9, and Ugt2b35 were
up-regulated by TCPOBOP in liver but were not changed in
intestine, therefore the pharmacological activation of CAR in liver
and intestine are not identical. Such tissue-speciﬁc effects may be
due to tissue-speciﬁc chromatin epigenetic environment, such as
different signatures for DNA methylation (suppressive signal for
gene transcription) and/or histone modiﬁcation patterns, which
prevent the CAR-mediated trans-activation of certain DPGs in
intestine. The epigenetic signatures within the enhancers and
promoters of certain DPGs will need to be examined in future
studies. Using the epithelial cells scraped from the whole small
intestine, another study in the literature has also shown liver- vs.
small intestine–speciﬁc regulation of some DPGs by TCPOBOP29.
Our ﬁnding is consistent with that study regarding the regulation
of Cyp2b10, Gsta1, Gstm2, Mrp2, and Mrp3, and in addition, the
present study has investigated the intestinal-speciﬁc CAR-
mediated regulation of many other genes, including Cyp3a13,
3a25, Cyp4a10, Cyp4b1, Nqo1, Gsta2, Gsta4, Gstt2, Gstt3,
Gstm3, Gstm4, Mrp4, and this has added new information to the
existing knowledge. Certain discrepancies are also observed
between the present study and the Maglich et al.29 study, in that
Aldh1a1, Aldh1a7, and Cyp3a11 were not changed in the whole
small intestine by TCPOBOP in the previous study, but were up-
regulated by TCPOBOP in the present study in a CAR-dependent
manner. In addition, the basal Cyp1a1 expression was decreased in
the previous study but increased in the present study. Such
discrepancy may be due to difference doses of TCPOBOP (a
single dose of TCPOBOP at 0.3 mg/kg in corn oil with 5% DMSO
of the previous study vs. 3 mg/kg of TCPOBOP in corn oil once
daily for 4-days in the present study), or different sample
preparation procedures (epithelial cells scraped from whole small
intestine in the previous study vs. various sections of small
intestine in the present study).
Previous studies have demonstrated that the basal expression of
Car is high in liver and small but is lower in the large intestine19,21,30,
whereas the present study has conﬁrmed the basal tissue distribution of
CAR, and is among the ﬁrst to show that pharmacological activation of
CAR by TCPOBOP actually down-regulates the Car expression in
liver, duodenum, and jejunum (Fig. 2), and this is likely due to a
negative feedback mechanism to prevent excessive CAR-signaling
through decreasing the CAR synthesis. Regarding the regulation of
DPGs by CAR, a previous study in the literature has demonstrated the
CAR-dependent up-regulation of Cyp2b10 in duodenum30. The presentstudy on Cyp2b10 in duodenum is consistent with that study, and our
study has also examined the expression of Cyp2b10 and other DPGs in
other sections of intestine. Another previous study has performed a
preliminary survey in WT male mice regarding the regulation of a few
Ugts by TCPOBOP in duodenum, jejunum, ileum, and colon using
pooled samples (i.e., 1 pooled sample from n¼5 biological repli-
cates)31. The apparent TCPOBOP-mediated increase in the mRNAs of
Ugt1a1 and Ugt2b35 in that previous study is consistent with the
present study, but Ugt2b34 mRNA is only up-regulated by TCPOBOP
in the present study. Such differences are likely due to different method
of detection (branched DNA ampliﬁcation technology vs. RT-qPCR),
and/or pooled vs. individual samples. Our ﬁnding on CAR-dependent
up-regulation of Ugt1a1 mRNA by TCPOBOP in duodenum is also
consistent with a previous study using Northern blot of Ugt1a1 in
duodenum of WT and Car / mice29. The expression of Car is
gender-divergent (i.e. higher in females than in males) in liver but not
in any sections of intestine19. Therefore, the present study has only
tested the effect of CAR activation in intestines of male mice.
Although many orally administered drug absorption and deliv-
ery are known to take place mostly in small intestine and liver, the
present study has shown that many bona ﬁde CAR-target DPGs in
liver and small intestine are highest expressed in colon, where
Car is lowly expressed. Examples of these genes include Aldh3b1,
Sult1c2, Sult1d1, Gstt3, Mrp3 and Mrp4. Functionally speaking,
the high expression of Aldh3b1 may be important in detoxifying
the microbial aldehyde produced from ethanol by the intestinal
bacteria, and this may be critical in reducing the risk of colon
cancer derived from microbial aldehyde32. The high expression of
certain phase-II enzymes such as Sults and Gst in colon correlate
with its critical function to conjugate and thus detoxify various
substances in large intestine. GSTs are also involved in the
metabolism of endogenous and exogenous carcinogenic sub-
stances, which are implicated in the risks of colorectal cancer33,34.
The colon-speciﬁc efﬂux transporters Mrp3 and Mrp4 may also
favor the elimination of various potentially toxic chemicals into
feces. Another functional signiﬁcant of colon-speciﬁc expression
of certain DPGs is that it is associated with the critical roles of
DPGs in metabolizing colon-targeted drugs or prodrugs. In
addition to the microbial enzymes capability to bio-activate and/
or detoxify xenobiotics, the colon tissue derived host enzymes may
also contribute to the biotransformation of certain chemicals.
One critical question that arises is in regard of the potential
species differences in the CAR-mediated regulation of intestinal
DPGs. CAR is highly expressed in liver and small intestine of both
mice and humans21,35. The species differences of CAR and its
tumorigenesis potential have been well characterized in liver, in
that pharmacological activation of mouse CAR leads hepatome-
galy followed by hepatocarcinogenesis in a CAR-dependent
manner36. Although human CAR activation is not a risk to cause
liver tumor in human, it may cause liver hypertrophy without
hyperplasia in response to the human CAR activators phenobarbi-
tal and chlordane, suggesting that hCAR is able to induce
hypertrophic responses in response to xenobiotic stress37. How-
ever, both the mouse and human CAR proteins appear to share
high similarities in regulating the genes involved in xenobiotic
biotransformation in liver. For example, the mouse CAR activation
by TCPOBOP up-regulates the expression of Cyp1a2, Cyp2b10,
Cyp3a11, and Ugt1a1 in a CAR-dependent manner in liver24,
whereas the human CAR activation by the human CAR activators
also up-regulates the expression of the human orthologs CYP1A2,
CYP2B6, and UGT1A129. In human intestine-derived Caco2 cells
phenobarbital up-regulates CYP2B6 and CYP3A438,39, and our
Shinhee Park et al.490ﬁnding regarding the CAR-mediated up-regulation of the mouse
orthologs Cyp2b10 and Cyp3a11 in duodenum is consistent with
the previous studies. However, relatively less is known regarding
the intestinal effect of pharmacological activation or genetic
depletion of Car in the regulation of many other DPGs in vivo,
thus the present study has ﬁlled this critical knowledge gap.
Identiﬁcation of the xenobiotic responses to CAR activation in
mouse and human intestines is critical for understanding certain
adverse drug reactions for orally exposed chemicals.
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